The clinical applications of heat shock protein inhibitors in cancer - Present and future

Current Cancer Drug Targets

Volumn 3, Issue 5, 2003, Pages 385-390

  Banerji, Udai ^a   Judson, Ian ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; BIOLOGICAL MARKER; CISPLATIN; COUMARIN DERIVATIVE; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; PACLITAXEL; PROTEIN INHIBITOR; RADICICOL; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG MECHANISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG TOLERANCE; HUMAN; IC 50; LIVER TOXICITY; MELANOMA; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; PARAMETER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; RIFABUTIN;

EID: 0141819944     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481813     Document Type: Review

References (37)

1. Gelmon, K. A.; Eisenhauer, E. A.; Harris, A. L.; Ratain, M. J.; Workman, P. Anticancer Agents Targeting Signalling Molecules and J. Natl. Cancer Inst. 1999, 91, 1281-1287.
2. Workman, P. Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship Between Pharmacokinetics and Pharmaeodynamics. Mol. Cancer Ther. 2003, 2, 131-138.
3. Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Whitesell, L.; Neckers, L. 17AAG - Low Target Binding Affinity and Potent Cell Activity: Finding an Explanation. Mol. Cancer Ther. 2003, 2, 123-129.
4. Maloney, A.; Workman, P. Hsp90 As a New Therapeutic Target for Cancer Therapy: The Story Unfolds. Expert Opin. Bio. Ther. 2002, 2, 3-24.
5. Kumar, V.; Green, S., Staub, A., Chambor, P. Localization of the Estradiol Binding and Putative DNA Binding Domains of the Human Oestrogen Receptor. EMBO J. 1986, 5, 2231-2236.
6. Grossmann, M. E.; Huang, H.; Tindall, D. Androgen Receptor Signalling in Androgen Refractory Prostate Cancer. J. Natl. Cancer Inst. 2001, 93, 1687-1697.
7. Slamon, D.; Pegram, M. Rational for Trastuzumab (Herceptin) in Adjuvant Breast Cancer Trials. Sem. Oncol. 2001, 28 (S 3), 9-13.
8. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.: Clegg, S. ; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, A. Mutations of the BRAF Gene in Human Cancer. Nature, 2002, 417, 949-954.
9. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, A.; Wooster, R.; Stratton M. R.; Weber, B. L. BRAF and RAS Mutations in Human Lung Cancer and Melanoma. Cancer Res. 2002, 62, 6997-7000.
10. Mauro, M. J.; O'Dwyer, M.; Heinrich, M. C.; Druker, B. J. STI571: a Paradigm of New Agents for Cancer Therapeutics. J. Clin. Oncol. 2002, 20, 325-334
11. Shayesteh, L.; Lu.; Kuo, W. L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G. B.; Gray, J. W. PI3CA is Implicated as an Oncogene in Ovarian Cancer. Nature Genet. 1999, 21, 99-102
12. Ma, Y. Y.; Wei, S. J.; Lin, Y. C.; Lung, J. C.; Chang, T. C., Whang-Peng, J.; Liu, J. M.; Yang, D. M.; Yang, W. K.; Shen, C. Y. PI3CA as an Oncogene in Cervical Cancer. Oncogene 2000, 19, 2739-2744.
13. Sui, L.; Dong, Y.; Ohno, M.; Goto, M.; Inohara, T.; Sugimoto, K.; Tai, Y.; Hando, T.; Tokuda, M. Inverse Expression of Cdk4 and p16 in Epithelial Ovarian Tumors. Gynecol. Oncol, 2000, 79, 230-237.
14. Bolen, J. B.; Veillette, A.; Schwartz, A. M.; Deseau, V.; Rosen, N. Activation of pp60c-Src Protein Kinase Activity in Human Colon Carcinoma Cell Lines. Proc. Natl. Acad. Sci. USA 1987, 84, 2251-2255
15. Egan, C.; Pang, A.; Durda, D.; Cheng, H. C.; Wang, J. H.; Fujita, D. J. Activation of Src in Human Breast Cancer Cell Lines: Elevated Levels of Phosphotyrosine Phosphatase Activity that Preferentially Recognizes the Src Carboxy Terminal Negative Regulatory Tyrosine Kinase 530. Oncogene, 1999, 18, 1227-37.
16. Bearss, D. J.; Hurley, L. H.; Von Hoff, D. D. Telomere Maintenance Mechanisms as a Target for Drug Development. Oncogene 2000, 19, 6632-6641.
17. Vogel, C.; Cobleigh, M. A.; Tripathy, D.; Gutheil, C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmorc, M.; Shak, S.; Stewart, S. J.; Press, M. J. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 2002, 20, 719-726.
18. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino, 17-Demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949.
19. Clarke, P. A.; Hostein, I.; Banerji, U.; Di Stefano, F.; Maloney, A.; Walton, M.; Judson, I.; Workman, P. Gene Expression Profiling of Colon Adenocarcinoma Cells Following Inhibition of Signal Transduction by 17-Allylamino-17-Demethoxygeldanamycin, an Inhibitor of the Hsp90 Molecular Chaperone. Oncogene 2000, 19, 4125-4133.
20. Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J. K.; Singh, S.; Millison, S. H.; Clarke, P. A.; Naaby-Hansen, S.; Stein, R.; Cramer, R.; Mollapour, M.; Workman, P.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Activation of the ATPase Activity of Hsp90 by Ahal, a Novel Stress-Regulated Co-Chaperone. Molec. Cell 2002, 10, 1307-1318.
21. Hostein, I.; Robertson, D.; Di Stefano, F.; Workman. P.; Clarke, P. A. Inhibition of Signal Transduction by the Hsp90 17-Allylamino17-Demethoxygeldanamycin Results in Cytostasis and Apoptosis. Cancer Res. 2001, 61, 4003-4009.
22. Munster, P.; Basso, A.; Solit, D.; Norton, L., Rosen L. Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-Induced Apoptosis in an RB- and Schedule-Dependent Manner. Clin. Cancer Res. 2001, 7, 2228-2236.
23. th.; Tabibi, E.; Schrump, D. S. Enhancement of Paclitaxel-Mediated Cytotoxicity in Lung Cancer Cells by 17-Allylamino Geldanamycin: In Vitro and in Vivo Analysis. Ann. Thorac. Surg. 2001, 72, 371-378.
24. Mauro, M. J.; O'Dwyer, M.; Heinrich, M. C.; Druker, B. J. STI571: a Paradigm of New Agents for Cancer Therapeutics. J. Clin. Oncol. 2002, 20, 325-334.
25. Workman, P.; Kaye, S. B. Translating Basic Cancer Research Into New Cancer Therapies. Trends Molec. Med. 2002. 8 (Suppl.), S1-S9
26. Workman, P. New Drug Targets for Genomic Cancer Therapy: Successes, Limitations, Opportunities and Future Challenges. Curr. Cancer Drug Targets, 2001, 1, 33-47.
27. Isaacs, J. S.; Xu, W.; Neckers, L. Heat Shock Protein 90 as a Molecular Target for Cancer Therapeutics. Cancer Cell 2003, 3 213-217.
28. Welch, W. J.; Feramisco, J. R. Purification of the Major Mammalian Heat Shock Proteins. J. Biol. Chem. 1982, 257, 14949-14959
29. Weinstein, I. B. Addiction to Oncogenes. Science 2002, 297, 63-64.
30. Workman, P. Cancer Genome Targets: RAF-Ing Up Tumour Cell to Overcome Oncogene Addiction. Expert Rev. Anticancer Ther. 2002, 2611-2614.
31. Smith, D. F.; Whitesell, L.; Katsanis, E. Molecular Chaperones: Biology and Prospects for Pharmacological Intervention. Pharmacol. Rev. 1998, 50, 493-514.
32. Chavany, C.; Mimnaugh, E.; Miller, P.; Bitton, R.; Nguyen, P.; Trepel, J.; Whitesell, L.; Schnur, R.; Moyer, J. D.; Neckers, L. p185erbb2 Binds to GRP94 in Vivo. Dissociation of the p185erbb2/GRP94 Heterocomplex by Benzoquinone Ansamycins Precedes Depletion of p185erbb2. J. Biol. Chem. 1996, 271, 4974-4977.
33. Soga, S.; Neckers, L.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a Novel Oxime Derivative of Radicicol, Exhibits in Vivo Anti Tumour Activity Via Selective Depletion of Hsp90 Binding Proteins. Cancer Res. 1999, 59, 2931-2938.
34. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-Binding Domain in the Carboxyl Terminus of the Chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
35. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumour Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
36. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, M. N., Zheng, F. F., Sepp-Lorenzino, L., Rosen, N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes HER-2 Degradation and the Growth Arrest and Differentiation of Breast Cancer. Chem. Biol. 2001, 8, 289-299.
37. Lui, D.; Hutchinson, O. C.; Osman, S.; Price, P.; Workman, P.; Aboagye, E. O. Use of Radiolabelled Choline as a Pharmacodynamic Marker for the Signal Transduction Inhibitor Geldanamycin. Br. J. Cancer, 2002, 87, 783.